Vietnam, France cooperate in trial production of drugs to treat COVID-19
Deputy Minister of Health Tran Van Thuan has just chaired an online meeting with Xenothera Company (France) on cooperation in phase 3 clinical trials and transferring to Vietnam technology for producing polyclonal antibodies XAV-19, treatment for COVID-19 researched and developed by this Company.
.jpg)
Illustration. Source: Internet.
XAV-19 infusion suspension is a polyclonal antibody specializing in the treatment of moderate SARS-CoV-2 patients, developed by Xenothera Company based on its proprietary antibody production technology, combining secrets in fields of genetics and immunology. The results of phase 1 and 2 clinical studies show that the drug is safe and effective in preventing the disease from getting worse, neutralizing the virus and reducing inflammation in patients.
The polyclonal property of XAV-19 has been shown to be effective against the SARS-CoV-2 variants that have been discovered to this time. This polyclonal antibody also has the ability to create immediate immunity and prevent viruses from entering cells. This is an important difference from the monoclonal antibodies being used to treat patients in the early stages of infection.
Phase 3 clinical trials of XAV-19 are currently being carried out in France and some European countries (Greece, Bulgaria, Romania, Spain and etc.).
The Chairman of Xenothera Company said that the company is ready to cooperate in phase 3 testing in Vietnam and expressed its goodwill to have a deeper discussion on technology transfer, so that Vietnam can proactively produce in the future.
Previously, at the end of May 2021, Xenothera Company also received an order from the French Ministry of Health and Solidarity to pre-order 30,000 doses of XAV-19, which is expected to begin supplying to patients in France after being approved. approved for use in emergency situations.
The Chairman of Xenothera Company said that the company is ready to cooperate in phase 3 testing in Vietnam and expressed its goodwill to have a deeper discussion on technology transfer, so that Vietnam can proactively produce in the future. .
Previously, at the end of May 2021, Xenothera Company also received an order from the French Ministry of Health and Solidarity to pre-order 30,000 doses of XAV-19, which is expected to begin supplying to patients in France after being approved for use in emergency situations.
Appreciating the encouraging results that XAV-19 has achieved after phase 1 and 2 clinical trials, Mr. Tran Van Thuan affirmed that Vietnam is ready to cooperate in phase 3 trials and receive technology transfer with the desire to soon supplement the source of drugs to treat COVID-19 patients in the country if the test results are positive.
Xenothera is a partner provided by Progressive International Joint Stock Company (AIC Group) to access, connect and introduce completely free of charge, so that the Ministry of Health and domestic experts and units can actively discuss and evaluate and find a cooperation plan, in order to proactively supply drugs to treat COVID-19 in Vietnam.
Immediately after the online meeting, through the connection of AIC Group, a domestic corporation, discussed specific contents and prepared to sign a memorandum of understanding on cooperation in phase 3 clinical trials and transfer technology XAV-19 to Xenothera Company.
ctngoc
www.khoahocphothong.com.vn